Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

…, C Maier, M Luedeke, T Schnoeller, J Kim… - Nature …, 2018 - nature.com
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified
more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data …

[HTML][HTML] Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

…, CG Drake, H Wu, P Qiu, J Kim… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Pembrolizumab has previously shown antitumor activity against programmed
death ligand 1 (PD-L1)–positive metastatic castration-resistant prostate cancer (mCRPC). Here…

[PDF][PDF] Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

…, RE Millikan, SM Tu, L Pagliaro, J Kim… - Journal of Clinical …, 2004 - researchgate.net
Purpose To determine the dose-limiting toxicity and maximum-tolerated dose of the
proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to …

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

…, D Daliani, CN Papandreou, TL Smith, J Kim… - The Lancet, 2001 - thelancet.com
Background Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated
the value of bonetargetedconsolidation therapy in selected patients with advanced …

Platinum-based chemotherapy for variant castrate-resistant prostate cancer

…, S Wen, JC Araujo, SM Tu, LC Pagliaro, J Kim… - Clinical cancer …, 2013 - AACR
Purpose: Clinical features characteristic of small-cell prostate carcinoma (SCPC), “anaplastic,”
often emerge during the progression of prostate cancer. We sought to determine the …

Fingerprinting the circulating repertoire of antibodies from cancer patients

PJ Mintz, J Kim, KA Do, X Wang, RG Zinner… - Nature …, 2003 - nature.com
Recognition of molecular diversity in disease is required for the development of targeted
therapies. We have developed a screening method based on phage display to select peptides …

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

…, T Karantanos, D Korentzelos, AK Azad, J Kim… - Science …, 2017 - science.org
Cancers with loss-of-function mutations in BRCA1 or BRCA2 are deficient in the DNA
damage repair pathway called homologous recombination (HR), rendering these cancers …

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward

…, R Lotan, BB Aggarwal, RS Bresalier, J Kim… - Clinical Cancer …, 2006 - AACR
This article reviews progress in chemopreventive drug development, especially data and
concepts that are new since the 2002 AACR report on treatment and prevention of …

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer

CJ Logothetis, GE Gallick, SN Maity, J Kim, A Aparicio… - Cancer discovery, 2013 - AACR
Recently, many therapeutic agents for prostate cancer have been approved that target the
androgen receptor and/or the prostate tumor microenvironment. Each of these therapies has …

Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable‐risk prostate cancer undergoing active surveillance

…, SJ Frank, AK Lee, CJ Logothetis, J Kim - BJU …, 2016 - Wiley Online Library
Objectives To evaluate prospectively the associations between illness uncertainty, anxiety,
fear of progression and general and disease‐specific quality of life (QoL) in men with …